

Amendments to the Specification:

Please replace the paragraph beginning at page 9, line 16, with the following rewritten paragraph:

11BD-2E11-2 prevented tumor growth and reduced tumor burden in a preventative *in vivo* model of human breast cancer. Monitoring continued past 280 days post-treatment. 40 percent of the 11BD-2E11-2 treatment group was still alive at over 7.5 months post-implantation. Conversely, the isotype control group had 100 percent mortality after 6.5 months post-treatment. At day 51 (soon after last treatment), the mean tumor volume in the 11BD-2E11-2 treated group was 20% of the isotype control ($p=0.0098$). Therefore 11BD-2E11-2 enhanced survival and decreased the tumor burden compared to the control-treated groups in a well-established model of human breast cancer.